Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM5 | P41594 | 11/20 | 0.60 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.48 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.37 |
| ▸ | PIK3CD | O00329 | 2/20 | 0.36 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.36 |
| ▸ | CACNA2D1 | P54289 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12526123 | 0.84 | GRM5 (0.64) | GRM5CYP11B2IRAK4PDE10A | |
| SCHEMBL18291839 | 0.82 | GRM5 (0.62) | GRM5CYP11B2IRAK4PDE10A | |
| SCHEMBL23111145 | 0.82 | GRM5 (0.62) | GRM5CYP11B2IRAK4PDE10A | |
| SCHEMBL21863669 | 0.78 | GRM5 (0.53) | GRM5CYP11B2IRAK4 | |
| SCHEMBL15889737 | 0.76 | GRM5 (0.65) | GRM5CYP11B2IRAK4PDE10A | |
| SCHEMBL46326 | 0.75 | GRM5 (0.57) | GRM5CYP11B2IRAK4 | |
| SCHEMBL15520747 | 0.74 | GRM5 (0.56) | GRM5CYP11B2IRAK4 | |
| SCHEMBL1053384 | 0.74 | GRM5 (0.56) | GRM5CYP11B2IRAK4 | |
| SCHEMBL2398608 | 0.74 | GRM5 (0.56) | GRM5CYP11B2IRAK4 | |
| SCHEMBL18307164 | 0.74 | GRM5 (0.56) | GRM5CYP11B2IRAK4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8349836-B2 | Phthalazine derivatives as inhibitors of protein kinase | ARALDI GIAN-LUCA (US) | 2013-01-08 | — | — | US | disclosed |
| US-8044041-B2 | e.g. 4-Chloro-1-hydroxy-phthalazine-6-carboxylic acid [4-chloro-3'-(2-dimethylamino-ethoxy)-biphenyl-3-yl]-amide; multifunctioning protein kinase inhibitors; anticarcinogenic, antiinflammatory, antidiabetic agent, neurodegenerative diseases | FOREST LABORATORIES HOLDINGS LIMITED (BM) | 2011-10-25 | — | — | US | disclosed |
| US-20110237571-A1 | PHTHALAZINE DERIVATIVES | ARALDI GIAN-LUCA | 2011-09-29 | — | — | US | disclosed |
| US-20080146547-A1 | PHTHALAZINE DERIVATIVES | FOREST LABORATORIES HOLDINGS LIMITED (BM) | 2008-06-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110237571-A1 | PHTHALAZINE DERIVATIVES | CDK5, HIPK2, PACSIN2 | GRM5 730/4885CYP11B2 2167/4885IRAK4 1004/4885 |
| US-20080146547-A1 | PHTHALAZINE DERIVATIVES | CDK5, HIPK2, PACSIN2 | GRM5 730/4885CYP11B2 2167/4885IRAK4 1004/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.